Dr. Shi-Wu Wen

Dr. Shi-Wu Wen

Profile

Dr. Shi-Wu Wen
Director, Education and Training, Clinical Epidemiology Program, Ottawa Hospital Research Institute
Senior Scientist, Clinical Epidemiology Program, Ottawa Hospital Research Institute
ProfessorAssociate

MD, PhD

Phone
613-737-8899 ext. 73912 (Office)
613-739-6266 (Fax)


Research

Perinatal epidemiology

Dr. Shi Wu Wen is a perinatal epidemiologist. Dr. Wen has obtained, together with Dr. Mark Walker, a Canadian Foundation for Innovation New Opportunities grant to establish a research infrastructure in the Department of Obstetrics and Gynecology. They have created a nationally recognized group in perinatal epidemiology, OMNI (Obstetrics and Maternal Newborn Investigations). They are one of the main themes of research in the clinical epidemiology program.

Supported by operating grants from CIHR, PSI and Sick Kids Foundation, Dr. Wen's current research focuses on the health effects of folic acid and prescription drugs in pregnancy. The training will be realized through supervised research projects for graduate students and post-MD or post-PhD fellows in perinatal health. For each trainee, we will develop an individualized, focused research project within the large-scale study.

Research personnel - OMNI

  • Shi Wu Wen, Co-Principal Investigator
  • Mark Walker, Director
  • Sarah McDonald, Investigator
  • Ruth Rennicks White, RN, Research Mgr
  • Diane Gorley, Research Administrative Assistant
  • Lily Gillen, Administrative Assistant
  • Wen Liang Zeng, Administrative Assistant
  • Dr. Qiuying Yang, Post-Doctoral Fellow
  • Dr. Xikuan Chen, International Post-Doctoral Fellow
  • Dr. Juan Vazquez, International Post-Doctoral Fellow
  • Lucy Chura, BScN
  • Melanie Good, RN
  • Laura Payant, BScN
  • Pauline Shields, RPN
  • Mandy Weselak, MSc
  • Fetal macrosomia and adult obesity and associated diseases in China. Canadian Diabetes Association, $3,000 Wen SW
  • CHOB Fetal macrosomia adolescent obesity. Canadian Diabetes Association, $224,333, (2004-2007) Wen SW, Walker, M, Sigal RJ, Nair, R, Mbikay, M.  
  • STIRRHS Bursary Benzodiazepines in pregnancy and birth defects. STIRRHS, $76,000, (2004-2006). Yang Q, Wen SW, Walker M.  
  • The development of collaborative research project in fetal macrosomia and adult obesity and associated diseases in China. Canadian Institute of Health Research, $22,250, (2004-2005) Wen SW, Walker M, Mbikay, M.  
  • ANTAG The use of folic acid antagonists in pregnancy and the incidence of major birth defects and severe fetal growth restriction. Canadian Institute of Health Research, $140,290, (2004-2007) Wen SW, Walker M (Co-PI), Nimrod C, Fraser W, Olatunbosum.  
  • Wyeth-CIHR Post-Graduate Fellowship Program. Wyeth/Canadian Institute of Health Research, $80,000, (2004-2005) Wen SW (Co-mentors), Walker M.  
  • Salary Award: Epidemiologic study of determinants of adverse pregnancy outcomes. Canadian Institute of Health Research, $300,000, (2002-2007)  
  • Infrastructure for Perinatal Epidemiology Unit, Canadian Foundation for Innovation, $849,988 (2001-2005) Walker M, Wen SW (Co-PIs)  
  • Infrastructure for Perinatal Epidemiology Unit Equipment, Canadian Foundation for Innovation, $101,966 (2003-2007). Walker M, Wen SW (Co-PIs)  
  • FAST - Folic Acid Deficiency in Second Trimester and Adverse Pregnancy Outcomes, $449,000 (2002-2005). Wen SW, Walker MC (Co-PIs), Rodger M, Perkins S, Sigal R  
  • SSRIs Selective serotonin reuptake inhibitors in pregnancy and adverse fetal and infant outcomes. Sick Kids Foundation, $124,650 (2002-2004). Wen SW, Walker M, Nimrod C, Fraser W.  
  • CDX Drugs Occurrence and determinants of exposure to FDA Class C,D,X Drugs in Pregnant Women, Physicians Services Incorporated, $104,000 (2002-2004). Wen SW, Walker M, Nimrod C, Fraser W, Olatunbosun O.  
  • Oocyte Program on Oocyte Health (Group grant), Canadian Institute for Health Research, $2,781,266 ($300,000 SW Wen as Co-Pi), 2003-2007) Baltz J, Chian RC, Claman P, Clarke H, Wen SW, Walker M.  
  • PE-NET Pre-eclampsia: Fetal & maternal outcomes and innovative therapies New Emerging Team, Canadian Institutes of Health Research, $1,739,481 (2003-2007). Smith G, Graham CH, Kisilevsky B, MacDonald S, Walker M, Wen SW.  
  • TIGRESS Thrombophilia and intrauterine growth restriction study, Canadian Institute for Health Research, $1,100,000 (2003-2008). Rodger M, Walker M, Wells P, Nair R, Wen SW.  
  • TOP-C Thrombophilia and outcomes of pregnancy cohort, Heart and Stroke Foundation, $131, 272 (2003-2005). Rodger M, Walker M, Wen SW, Wells P.  
  • Cardiovascular and endocrine effects in childhood of inutero exposure to corticosteroids, Physicians Services Incorporated $162,000 (2001-2004). Walker M, Lougheed J, Gibb W, Nimrod C, Walker R, Lawson M, Wen SW.  
  • PREA Genetic and environmental determinants of adverse pregnancy outcomes. Premiers Research Excellence Award, $150,000 (2003-2008). Wen SW, Walker M.  
  • Post-Graduate Fellowship Program 2004. Wyeth Pharmaceuticals and Canadian Institute for Research Rx&D Research Program, $40,000/yr approx. (2004-2005, Wen SW, Walker M (Co-mentors).  
  • Global Health Initiative (Seed Funding), Ottawa Health Research Institute, $20,000  
  • Rx&D Special Research Allowance, Canadian Institutes of Health Research, $37,500 (2002-2003)

Research interests

  • Perinatal and reproductive Health